BERWYN, Pa.--(BUSINESS WIRE)--Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., has launched LACRIFILL Canalicular Gel, a novel therapy for dry eye in the U.S. LACRIFILL Canalicular Gel is a cross-linked hyaluronic acid derivative and is FDA-cleared to temporarily block tear drainage by the occlusion of the canalicular system..

宾夕法尼亚州伯温（商业新闻短讯）--北欧集团（Nordic Group B.V.）的子公司北欧制药公司（Nordic Pharma，Inc.）推出了LACRIFILL泪小管凝胶，这是一种治疗美国干眼症的新型疗法。LACRIFILL泪小管凝胶是一种交联透明质酸衍生物，经FDA批准可通过阻塞泪小管系统暂时阻断泪液引流。。

LACRIFILL Canalicular Gel allows patient’s eyes to be bathed in their own natural tears. It is customized for each individual patient and provides a full fill of the canalicular system. LACRIFILL Canalicular Gel is administered through a simple in-office procedure, which is reimbursed through the existing CPT code (68761), and the results last for six months..

LACRIFILL泪小管凝胶可以让患者的眼睛沐浴在自己的自然眼泪中。它是为每个患者定制的，并提供完整的小管系统。LACRIFILL小管凝胶通过简单的办公室程序给药，通过现有的CPT代码（68761）报销，结果持续六个月。。

“It’s been so exciting to be part of the launch of LACRIFILL Canalicular Gel, an interventional dry eye treatment that helps ophthalmologists with cataract, glaucoma and refractive surgeries and all of their dry eye needs. This dry eye therapy is truly changing practice and changing lives,” said Chief Commercial Officer of Eye Care U.S., Jai Parekh, MD, MBA..

“作为LACRIFILL小管凝胶推出的一部分，这是一种介入性干眼症治疗方法，可以帮助眼科医生治疗白内障、青光眼和屈光手术以及他们所有的干眼症需求。这种干眼症治疗方法正在真正改变实践，改变生活，”美国眼科护理首席商务官Jai Parekh，医学博士，MBA说道。。

Nordic Pharma is attending Kiawah Eye 2024 in Kiawah Island, SC from May 30-June 1 to share information about LACRIFILL Canalicular Gel and take orders. 'LACRIFILL Canalicular Gel is a disruptive technology that will change how ophthalmologists practice,” said Program Director for Kiawah Eye and chairperson of the LACRIFILL U.S.

北欧制药（Nordic Pharma）将于5月30日至6月1日参加位于南卡罗来纳州嘉华岛的嘉华眼科2024，分享有关LACRIFILL小管凝胶的信息并接受订单。”LACRIFILL小管凝胶是一项颠覆性技术，它将改变眼科医生的实践方式，”Kiawah Eye项目总监兼LACRIFILL U.S.主席说。

Medical Advisory Board, Eric D. Donnenfeld, MD. “Having Nordic Pharma onsite to discuss how LACRIFILL Canalicular Gel will optimally occlude the canalicular system to maximize tear film preservation in patients with dry eye symptoms will be incredibly beneficial for Kiawah Eye attendees.”.

医学顾问委员会，Eric D.Donnenfeld，MD。“让北欧制药公司在现场讨论LACRIFILL泪小管凝胶如何最佳地阻塞泪小管系统，以最大限度地保留干眼症患者的泪膜，这将对Kiawah眼科参与者非常有益。”。

For more information about LACRIFILL Canalicular Gel and ordering details visit lacrifill.com.

有关LACRIFILL小管凝胶的更多信息和订购详细信息，请访问LACRIFILL.com。

About Nordic Group B.V.

关于北欧集团B.V。

Nordic Group B.V. is a privately owned, medium-size international pharmaceutical company which focuses on the development and commercialization of specialty products. Portfolio enhancement has been accomplished through targeted developments and focused acquisitions to build a foundation in Eye Care, Rheumatology and Women’s Health.

北欧集团（Nordic Group B.V.）是一家私营中型国际制药公司，专注于特种产品的开发和商业化。通过有针对性的开发和重点收购，为眼部护理、风湿病和妇女健康奠定了基础，从而实现了投资组合的增强。

Nordic Group has established deep roots throughout Europe, and more recently, expanded outside of Europe with increased acquisitions worldwide..

北欧集团在整个欧洲都建立了深厚的根基，最近，随着全球收购的增加，该集团在欧洲以外扩张。。

Nordic Group is a part of SEVER Life Sciences, a holding company created in 2019 that brings together three diverse but complementary companies that offer a wide range of products, pharmaceutical development services and delivery technologies.

北欧集团是SEVER Life Sciences的一部分，SEVER Life Sciences是一家成立于2019年的控股公司，汇集了三家多元化但互补的公司，提供广泛的产品、药物开发服务和交付技术。

About Nordic Pharma, Inc.

关于北欧制药公司。

Nordic Pharma, Inc., subsidiary of Nordic Group B.V., is partnered with well-established global biopharmaceutical companies and is uniquely positioned to leverage its expertise in bringing biotechnology derived medicines, sterile manufacturing and other state-of-the-art technologies to the marketplace..

北欧集团（Nordic Group B.V.）的子公司北欧制药公司（Nordic Pharma，Inc.）与知名的全球生物制药公司合作，拥有独特的优势，可以利用其专业知识将生物技术衍生的药物、无菌制造和其他最先进的技术推向市场。。

Safe Harbor

安全港

This press release contains forward-looking statements, including, without limitation, statements related to Nordic Group /Nordic Pharma’s business developments and the implementation of Nordic Group /Nordic Pharma’s strategic initiatives. Because these statements reflect Nordic Group /Nordic Pharma’s current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties that could cause actual developments and results to differ materially from Nordic Group /Nordic Pharma’s expectations.

本新闻稿包含前瞻性声明，包括但不限于与北欧集团/北欧制药业务发展和北欧集团/北欧制药战略举措实施相关的声明。由于这些声明反映了北欧集团/北欧制药公司对未来事件的当前观点、期望和信念，因此这些前瞻性声明涉及风险和不确定性，可能导致实际发展和结果与北欧集团/北欧制药公司的期望大不相同。

These factors include, but are not limited to, general market conditions, regulatory trends, changes in the financial conditions of third parties dealing with Nordic Group /Nordic Pharma, and other factors that could affect Nordic Group /Nordic Pharma’s business and financial performance. Nordic Group /Nordic Pharma does not assume any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise..

这些因素包括但不限于一般市场状况、监管趋势、与北欧集团/北欧制药交易的第三方财务状况的变化，以及可能影响北欧集团/北欧制药业务和财务业绩的其他因素。北欧集团/北欧制药不承担任何义务公开更新任何前瞻性声明，无论是由于新信息、未来发展还是其他原因。。